The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.

Elaine SilveiraIsadora Pontes CavalcanteJean Lucas KremerPedro Omori Ribeiro de MendonçaClaudimara Ferini Pacicco Lotfi

Published in: Cancer cell international (2018)

Taken together, our data identified nilotinib as a cytotoxic drug that combined with ERK inhibitors deserves to be tested as a novel therapy for adrenocortical carcinoma.

Keyphrases

chronic myeloid leukemia
signaling pathway
electronic health record
cell proliferation
big data
pi k akt
adverse drug
artificial intelligence
anti inflammatory